Selinexor Can Inhibit Multiple Targets of the JAK Pathway, Enabling Independent Suppression of MF cells and Potentially Complementing the Function of JAKi's1,2,3,4,5 | --- | --- | --- | --- | --- | --- | |---------------------------------------------------------------|-------------------------------------------------------------|-------|--------------------------------------------------------------------------|-------|-------| | MF is driven by upstream mutations JAK2, CALR MPL \nof or | | Par-4 | Additiona ...

1 ©2023 KARYOPHARM THERAPEUTICS INC. A Commercial-Stage Pharmaceutical Company Pioneering Novel Cancer Therapies JP MORGAN 2023 HEALTHCARE CONFERENCE January 11, 2023 2 ©2023 KARYOPHARM THERAPEUTICS INC. Richard Paulson Chief Executive Officer OVERVIEW 400 Forward-looking Statements and Other Important Information This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding Karyopharm ...

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q3 2022 Earnings Conference Call November 3, 2022 4:30 PM ET Company Participants Elhan Webb - Senior Vice President-Investor Relations Richard Paulson - President & Chief Executive Officer Sohanya Cheng - Chief Commercial Officer Reshma Rangwala - Chief Medical Officer Mike Mason - Chief Financial Officer Conference Call Participants Kevin Strang - Jefferies Abi Gray - R.W. Baird Brian Abrahams - RBC Capital Markets Eric Joseph - JPMorgan Operator Good afternoon. ...

1 ©2022 KARYOPHARM THERAPEUTICS INC. Third Quarter 2022 Financial Results & Business Update November 3, 2022 On Today's Call • Welcome Elhan Webb, CFA, Senior Vice President, Investor Relations • Overview Richard Paulson, President and Chief Executive Officer • Commercial Highlights Sohanya Cheng, Chief Commercial Officer • Pipeline Update Dr. Reshma Rangwala, Chief Medical Officer • Financial Summary and Guidance Michael Mason, Chief Financial Officer • Closing Remarks Richard Paulson, President and Chief ...

Karyopharm Therapeutics, Inc. (NASDAQ:KPTI) Q2 2022 Results Conference Call August 4, 2022 8:00 AM ET Company Participants Elhan Webb - SVP, IR Richard Paulson - President, CEO & Director Sohanya Cheng - EVP & Chief Commercial Officer Mike Mason - EVP, CFO & Treasurer Reshma Rangwala - Chief Medical Officer Conference Call Participants Kevin Strang - Jefferies Peter Lawson - Barclays Mike Ulz - Morgan Stanley Colleen Kusy - Baird Eric Joseph - JP Morgan Ed White - H.C Faisal Khurshid - SVB Securities Operat ...

1 ©2022 KARYOPHARM THERAPEUTICS INC. May 2022 A Commercial-Stage Pharmaceutical Company Pioneering Novel Cancer Therapies Forward-looking Statements and Other Important Information This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding Karyopharm's guidance on its 2022 net product revenue and 2022 non-GAAP research and development and selling, general and administrative expenses ...

1 ©2022 KARYOPHARM THERAPEUTICS INC. May 2022 A Commercial-Stage Pharmaceutical Company Pioneering Novel Cancer Therapies Forward-looking Statements and Other Important Information This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding Karyopharm's guidance on its 2022 net product revenue and 2022 non-GAAP research and development and selling, general and administrative expenses ...

1 ©2022 KARYOPHARM THERAPEUTICS INC. First Quarter 2022 Financial Results & Business Update May 5, 2022 On Today's Call • Welcome Elhan Webb, Senior Vice President, Investor Relations • Overview Richard Paulson, President and Chief Executive Officer • Commercial Highlights Sohanya Cheng, Chief Commercial Officer • Pipeline Update Dr. Reshma Rangwala, Chief Medical Officer Dr. Patricia Judson, Senior Vice President, Medical Strategy • Financial Summary and Guidance Michael Mason, Chief Financial Officer • Cl ...

Karyopharm Therapeutics, Inc. (NASDAQ:KPTI) Q1 2022 Earnings Conference Call May 5, 2022 8:30 AM ET Company Participants Elhan Webb - SVP, IR Richard Paulson - President, CEO & Director Sohanya Cheng - EVP & Chief Commercial Officer Michael Mason - EVP, CFO & Treasurer Reshma Rangwala - Chief Medical Officer Patricia Judson - SVP, Medical Strategy Conference Call Participants Maurice Raycroft - Jefferies Peter Lawson - Barclays Bank Michael Ulz - Morgan Stanley Faisal Khurshid - SVB Leerink Edward White - H ...

1 ©2022 KARYOPHARM THERAPEUTICS INC. A Commercial-Stage Pharmaceutical Company Pioneering Novel Cancer Therapies March 2022 Forward-looking Statements and Other Important Information This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding Karyopharm's guidance on its 2022 net product revenues and 2022 non-GAAP research and development and selling, general and administrative expen ...